Russell-Jones, David

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 835

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 402

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 219

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

Russell-Jones, D., Simpson, R., Hylleberg, B., Draeger, E., & Bolinder, J. (2004) · Clinical Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 194

Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (ONSET 1)

Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 177

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

Russell-Jones, D. (2009) · Molecular and Cellular Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 137

Insulin-sensitizing effects on muscle and adipose tissue after dietary fiber intake in men and women with metabolic syndrome

Robertson, M. D., Wright, J. W., Loizon, E., Debard, C., Vidal, H., Shojaee-Moradie, F., Russell-Jones, D., & Umpleby, A. M. (2012) · The Journal of Clinical Endocrinology & Metabolism

Food composition and propertiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 126

Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial

Russell-Jones, D., Babazono, T., Cailleteau, R., Engberg, S., Irace, C., Kjaersgaard, M. I. S., Mathieu, C., Rosenstock, J., Woo, V., & Klonoff, D. C. (2023) · The Lancet

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 115

Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men

Robertson, M. D., Russell-Jones, D., Umpleby, A. M., & Dijk, D.-J. (2013) · Metabolism

Sleep and related disordersSleep and Work-Related Fatigue

Cited by 100

Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. Insulin glargine: A meta-analysis of seven clinical trials

Russell-Jones, D., Gall, M.-A., Niemeyer, M., Diamant, M., & Del Prato, S. (2015) · Nutrition, Metabolism and Cardiovascular Diseases

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 66

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance

Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementLipid metabolism and disorders

Cited by 32

An evaluation of the safety of pilots with insulin-treated diabetes in Europe flying commercial and noncommercial aircraft

Garden, G. L., Hine, J. L., Mitchell, S. J., Hutchison, E. J., Gaffney, T. P., Hofmann, V., Frier, B. M., Shaw, K. M., Heller, S. R., Koehler, G., et al. (2020) · Diabetes Care

Diabetes Management and ResearchPatient Safety and Medication Errors

Cited by 17